• Policy
• IVI-Biovac has signed an agreement to develop an OCV
• by Lee, Hye-Kyung Nov 28, 2022 05:49am

• Policy
• SGLT2+DPP4 standards expanded, will it be over again?
• by Lee, Tak-Sun Nov 24, 2022 05:51am

• Policy
• COVID vaccine side effects proven by the Government
• by Kim, Jung-Ju Nov 24, 2022 05:50am

• Policy
• The government are in full swing discussing support
• by Lee, Jeong-Hwan Nov 24, 2022 05:50am

• Policy
• Gov’t to increase drug price reference countries
• by Lee, Tak-Sun Nov 23, 2022 06:04am

• Policy
• MFDS recruits companies to develop 6 National Essential Drug
• by Lee, Hye-Kyung Nov 23, 2022 06:04am

• Policy
• Forxiga Prodrug will be reimbursed for five months
• by Lee, Tak-Sun Nov 23, 2022 06:04am

• Policy
• Reimb standards will be newly established for Coagadex
• by Kim, Jung-Ju Nov 22, 2022 06:04am

• Policy
• Phase 3 of Fitusiran, an all-around tx for hemophilia
• by Lee, Hye-Kyung Nov 22, 2022 06:04am

• Policy
• Gov't declines preferential pricing for innovative drugs
• by Lee, Jeong-Hwan Nov 21, 2022 05:56am